SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
About this trial
This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and/or liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures, spheroids, and organoids) to study colorectal cancer stem cells. The main objective is to investigate the role of the lysine methyltransferase SMYD3 in metabolic reprogramming and adaptation to oxidative stress that enable colorectal cancer cells to survive and grow in the liver. Previous work has shown that SMYD3 is overexpressed in colorectal cancer, promotes drug resistance, and regulates key oncogenic pathways, including c-MYC and the AMPK/mTOR axis. By identifying SMYD3-dependent pathways and pharmacologic vulnerabilities in cancer stem cells within liver metastases, this study aims to support the development of new therapeutic strategies that combine SMYD3 inhibitors with approved or experimental agents targeting tumor metabolism and oxidative stress responses
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years.
Availability of residual tumor tissue from the surgical procedure that is not required for diagnostic purposes.
Signed written informed consent for the use of biological samples for research purposes.
Disqualifiers
Age < 18 years.
Undergoing surgical intervention for a malignancy other than those specified in the inclusion criteria.
Lack of signed informed consent
Trial population
This study is a multicenter prospective observational study and involves the collection of biological samples from patients undergoing surgery for CRC and/or liver metastases
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
156 Participants
are grouped into 3 trial groupsGroup A: Patients with CRC (colorectal cancer)
Group B: Patients with colorectal cancer (CRC) and liver metastase
Group C: Patients with liver metastase
Trial outcomes
Primary outcomes
1
Molecular and Cellular mechanisms
Identification of the molecular and cellular mechanisms involved in metastatic progression that depend on the methyltransferase SMYD3
Time frame
At the time of the surgeryLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Lead sponsor
University of Bari
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: